Viking Therapeutics shares have surged about 45% in October, their best month of 2025, driven by excitement around its obesity drug VK2735. Traders linked Novo Nordisk's renewed Metsera bid to rising competition from Viking, while Pfizer's obesity drug setbacks fuelled speculation that Viking could become a potential acquisition target.